Sana Karam, MD, PhD | Profiles | School ...

Dr. Sana D. Karam

Claim this profile

University of Colorado Hospital

Studies Squamous Cell Carcinoma
Studies Oral Squamous Cell Carcinoma
5 reported clinical trials
12 drugs studied

Area of expertise

1

Squamous Cell Carcinoma

Sana D. Karam has run 4 trials for Squamous Cell Carcinoma. Some of their research focus areas include:

p16 negative
Stage IV
Stage III
2

Oral Squamous Cell Carcinoma

Sana D. Karam has run 1 trial for Oral Squamous Cell Carcinoma. Some of their research focus areas include:

p16 negative
EGFR positive
EGFR negative

Affiliated Hospitals

Image of trial facility.

University Of Colorado Hospital

Image of trial facility.

Colorado Research Center

Clinical Trials Sana D. Karam is currently running

Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

Recruiting

1 award

Phase 2 & 3

21 criteria

Image of trial facility.

TTI-101 + Radiotherapy

for Pancreatic Cancer

To evaluate the safety and tolerability of TTI-101 given in combination with Stereotactic Body Radiation Therapy (SBRT) in borderline resectable and locally advanced pancreatic ductal adenocarcinoma.

Recruiting

1 award

Phase 1 & 2

17 criteria

More about Sana D. Karam

Clinical Trial Related

12 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Sana D. Karam has experience with

  • Atezolizumab
  • Cetuximab
  • Durvalumab
  • Standard Of Care Therapy
  • Stereotactic Body Radiation Therapy (SBRT)
  • Cisplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Sana D. Karam specialize in?

Is Sana D. Karam currently recruiting for clinical trials?

Are there any treatments that Sana D. Karam has studied deeply?

What is the best way to schedule an appointment with Sana D. Karam?

What is the office address of Sana D. Karam?

Is there any support for travel costs?